Revenues

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Revenues

5. Revenues

Revenues by product line. The following table represents total net revenues by product line:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
COVID-19 (1)	$	43,378	$	12,070	$	74,411	$	40,215
Genomics (1)		15,486		19,498		30,578		30,316
HIV		10,357		10,944		18,523		19,722
HCV		3,691		4,300		6,948		6,668
Substance abuse		2,630		2,629		5,191		4,591
Microbiome (1)		1,832		2,447		3,822		4,198
Laboratory services		1,204		3,114		2,938		5,611
Other product and service revenues		589		739		1,992		999
Net product and services revenues		79,167		55,741		144,403		112,320
Royalty income		642		875		1,326		2,136
Other non-product revenues		422		991		2,209		1,733
Other revenues		1,064		1,866		3,535		3,869
Net revenues	$	80,231	$	57,607	$	147,938	$	116,189

(1) 2021 COVID-19, Genomics and Microbiome revenues were reclassified to reflect the correct classification of the product line sales. The reclassification increased (decreased) the product line revenues for the three months ended June 30, 2021 by $490, $(84) and $(406), respectively. The reclassification increased (decreased) the product line revenues for the six months ended June 30, 2021 by $1,073, $(330) and $(743), respectively.

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
United States	$	70,320	$	47,601	$	128,307	$	96,700
Europe		2,436		3,325		6,722		7,877
Other regions		7,475		6,681		12,909		11,612
	$	80,231	$	57,607	$	147,938	$	116,189

Customer and Vendor Concentrations. At June 30, 2022, one non-commercial customer accounted for 48% of our accounts receivable and another commercial customer accounted for 10% of our accounts receivable. No customers accounted for more than 10% of our accounts receivable as of December 31, 2021. One non-commercial customer accounted for 56% and 39% of net consolidated revenues for the three and six months ended June 30, 2022. One customer accounted for 14% of net consolidated revenues for the three months ended June 30, 2021. Another customer accounted for 10% and 14%, respectively, of net consolidated revenues for the three and six months ended June 30, 2021.

We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Third-party suppliers also manufacture certain products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of June 30, 2022 and December 31, 2021 includes customer prepayments of $1,746 and $1,843, respectively. Deferred revenue as of June 30, 2022 and December 31, 2021 also includes $914 and $1,093, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that average price.